Westerkirk Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Westerkirk Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.14M	Sell	4,802 -269	-5%	-$125K	0.23%	80
2025 Q4	$2.3M	Buy	5,071 +429	+9%	+$185K	0.22%	79
2025 Q3	$1.82M	Buy	4,642 +1,842	+66%	+$770K	0.21%	93
2025 Q2	$1.25M	Buy	+2,800	New	+$1.29M	0.15%	124

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Westerkirk Capital's VRTX Position: Q1 2026 in Review

Westerkirk Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 5.3% in Q1 2026, selling an estimated $125K and leaving 4,802 shares worth $2.14M. The position accounts for 0.23% of the portfolio, ranked #80.

Westerkirk Capital first reported a position in VRTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.3M in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Westerkirk Capital held 4,802 shares of Vertex Pharmaceuticals worth $2.14M as of Q1 2026.
Westerkirk Capital sold 269 Vertex Pharmaceuticals shares in Q1 2026, an estimated $125K.
Vertex Pharmaceuticals made up 0.23% of Westerkirk Capital's portfolio in Q1 2026, its #80 holding.
Westerkirk Capital first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
Westerkirk Capital's Vertex Pharmaceuticals position peaked at $2.3M in Q4 2025.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Westerkirk Capital's 13F filing for Q1 2026, filed 14 May 2026.